A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Conditions:   Advanced Solid Tumors (Part A/B/C/D);   Non-small Cell Lung Cancer (Part E);   Melanoma (Part E);   Squamous Cell Cancer of the Head and Neck (Part E)
Interventions:   Drug: IPI-549;   Drug: Nivolumab
Sponsor:   Infinity Pharmaceuticals, Inc.
Recruiting - verified November 2016

http://ift.tt/2fcMHZn